Effect of serotonin modulation on dystrophin-deficient zebrafish.

ABSTRACT: Duchenne muscular dystrophy (DMD) is a progressive muscle-wasting disease caused by mutation of the dystrophin gene. Pharmacological therapies that function independently of dystrophin and complement strategies aimed at dystrophin restoration could significantly improve patient outcomes. Previous observations have suggested that serotonin pathway modulation ameliorates dystrophic pathology, and re-application of serotonin modulators already used clinically would potentially hasten availability to DMD patients. In our study, we used dystrophin-deficient sapje and sapje-like zebrafish models of DMD for rapid and easy screening of several classes of serotonin pathway modulators as potential therapeutics. None of the candidate drugs tested significantly decreased the perce

SUBMITTER: Spinazzola JM 

PROVIDER: S-EPMC7473644 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature